1. Co-Spray-Dried Urea Cross-Linked Hyaluronic Acid and Sodium Ascorbyl Phosphate as Novel Inhalable Dry Powder Formulation
- Author
-
Maliheh Ghadiri, Arianna Fallacara, Daniela Traini, Paul M. Young, Hui Xin Ong, Stefano Manfredini, Michele Pozzoli, and Laura Busato
- Subjects
Lung Diseases ,Antioxidant ,genetic structures ,Chemistry, Pharmaceutical ,Drug Compounding ,medicine.medical_treatment ,Anti-Inflammatory Agents ,Pharmaceutical Science ,Ascorbic Acid ,02 engineering and technology ,030226 pharmacology & pharmacy ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Drug Stability ,SODIUM ASCORBYL PHOSPHATE ,Cell Line, Tumor ,Administration, Inhalation ,Hyaluronic acid ,medicine ,Humans ,Urea ,Desiccation ,Hyaluronic Acid ,Particle Size ,Aerosols ,Spray dried ,Chromatography ,Chemistry ,Cell model ,Dry Powder Inhalers ,021001 nanoscience & nanotechnology ,Drug Combinations ,Cross-Linking Reagents ,Dry powder ,Particle size ,Powders ,0210 nano-technology - Abstract
The pathogenesis and progression of several lung disorders is propagated by inflammatory and oxidative processes, which can be controlled by adjunctive inhaled therapies. The present study aimed to develop an inhalable dry powder formulation consisting of co-spray-dried urea-crosslinked hyaluronic acid and sodium ascorbyl phosphate (SD HA-CL–SAP), a novel combination which was recently shown to possess anti-inflammatory, antioxidant, and wound healing properties. Native HA and SAP were co-spray dried (SD HA–SAP) and evaluated as control formulation. Yield (Y%) and encapsulation efficiency (EE%) were 67.0 ± 4.8% and 75.5 ± 7.2% for SD HA–SAP, 70.0 ± 1.5% and 66.5 ± 5.7% for SD HA-CL–SAP, respectively. Both formulations were shown to be suitable for lung delivery in terms of morphology, particle size (median volumetric diameter ∼ 3.4 μm), physical and thermal stability, in vitro aerosol performance - respirable fraction: 30.5 ± 0.7% for SD HA–SAP and 35.3 ± 0.3% for SD HA-CL–SAP. SAP release was investigated using Franz cells and air-interface Calu-3 cell model (>90% of SAP transported within 4 h). The innovative SD HA-CL–SAP formulation holds potential as inhalable dry powder for the treatment of inflammatory lung disorders.
- Published
- 2019